Romain Lelong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Romain Lelong has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abdelmalek Mouazer
Laboratory of Medical Informatics and Knowledge Engineering in e-Health INSERM Université Sorbonne Paris Nord Sorbonne Université LIMICS Paris France
1 shared publication - Catherine Letord
Centre Hospitalier Universitaire de Rouen, Département de Santé numérique, INSERM, Sorbonne Université, Université Sorbonne Paris Nord, Laboratoire d’Informatique Médicale et d’Ingénierie des connaissances en e-Santé, LIMICS, 76000 Rouen, France
1 shared publication - Christian Simon
EIG SAS 92400 Courbevoie France
1 shared publication - Hector Falcoff
SFTG Recherche (Société de Formation Thérapeutique du Généraliste) Paris France
1 shared publication - Jean-Baptiste Lamy
Sorbonne Université, INSERM, Université Sorbonne Paris Nord, LIMICS, Paris France
1 shared publication - Julien Grosjean
Department of Biomedical Informatics, Rouen University Hospital, Rouen, France
1 shared publication
Latest Publications
- Open Access
A randomized simulation trial evaluating ABiMed, a clinical decision support system for medication reviews and polypharmacy management
Background: Medication review is a structured interview of the patient, performed by the pharmacist and aimed at optimizing drug treatments. In practice, medication review is a long and cognitively-demanding task that requires specific knowledge. Clinical practice guidelines have been proposed, but their application is tedious. Methods: We designed ABiMed, a clinical decision support system for medication reviews, based on the implementation of the STOPP/START v2 guidelines and on the visual presentation of aggregated drug knowledge using tables, graphs and flower glyphs. We evaluated ABiMed with 39 community pharmacists during a randomized simulation trial, each pharmacist performing a medication review for two fictitious patients without ABiMed, and two others with ABiMed. We recorded the problems identified by the pharmacists, the interventions proposed, the response time, the perceived usability and the comments. Pharmacists' medication reviews were compared to an expert-designed gold standard. Results: With ABiMed, pharmacists found 1.6 times more relevant drug-related problems during the medication review (p=1.1e-12) and proposed better interventions (p=9.8e-9), without needing more time (p=0.56). The System Usability Scale score is 82.7, which is ranked "excellent". In their comments, pharmacists appreciated the visual aspect of ABiMed and its ability to compare the current treatment with the proposed one. A multifactor analysis showed no difference in the support offered by ABiMed according to the pharmacist's age or sex, in terms of percentage of problems identified or quality of the proposed interventions. Conclusions: The use of an intelligent and visual clinical decision support system can help pharmacists when they perform medication reviews. Our main perspective is the validation of the system in clinical conditions.
Open AccessA randomized simulation trial evaluating ABiMed, a clinical decision support system for medication reviews and polypharmacy management
Background: Medication review is a structured interview of the patient, performed by the pharmacist and aimed at optimizing drug treatments. In practice, medication review is a long and cognitively-demanding task that requires specific knowledge. Clinical practice guidelines have been proposed, but their application is tedious. Methods: We designed ABiMed, a clinical decision support system for medication reviews, based on the implementation of the STOPP/START v2 guidelines and on the visual presentation of aggregated drug knowledge using tables, graphs and flower glyphs. We evaluated ABiMed with 39 community pharmacists during a randomized simulation trial, each pharmacist performing a medication review for two fictitious patients without ABiMed, and two others with ABiMed. We recorded the problems identified by the pharmacists, the interventions proposed, the response time, the perceived usability and the comments. Pharmacists' medication reviews were compared to an expert-designed gold standard. Results: With ABiMed, pharmacists found 1.6 times more relevant drug-related problems during the medication review (p=1.1e-12) and proposed better interventions (p=9.8e-9), without needing more time (p=0.56). The System Usability Scale score is 82.7, which is ranked "excellent". In their comments, pharmacists appreciated the visual aspect of ABiMed and its ability to compare the current treatment with the proposed one. A multifactor analysis showed no difference in the support offered by ABiMed according to the pharmacist's age or sex, in terms of percentage of problems identified or quality of the proposed interventions. Conclusions: The use of an intelligent and visual clinical decision support system can help pharmacists when they perform medication reviews. Our main perspective is the validation of the system in clinical conditions.